Cargando…
SUN-LB112 Efficacy & Safety After Switchover to Remogliflozin in Indian T2DM Patients - a Real World Study
INTRODUCTON: Remogliflozin is new SGLT2i recently approved in India, but more economical than the previously available SGLT2i. It is prudent to evaluate its effectiveness & tolerability in comparison to other SGLT2i in real world setting. METHODS: In this observational retrospective study, medic...
Autores principales: | Bhattacharyya, Supratik, Katare, Sagar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208915/ http://dx.doi.org/10.1210/jendso/bvaa046.2146 |
Ejemplares similares
-
SUN-LB117 Faster Acting Insulin Aspart in Patients With Gestational Diabetes Mellitus - an Early Experience From India
por: Bhattacharyya, Supratik
Publicado: (2020) -
Clinical Effectiveness and Safety of Gliclazide MR and Linagliptin Combination in the Management of Patients With T2DM and Chronic Kidney Disease (CKD) Switched From Glimepiride - a Real-World, Retrospective, Observational Study
por: Bhattacharyya, Supratik, et al.
Publicado: (2021) -
SUN-LB030 Empagliflozin Causing Euglycemic Diabetic Ketoacidosis
por: Thomas, Mathew, et al.
Publicado: (2019) -
SUN-LB028 Diabetic Truncal Radiculopathy: An Underrecognized Cause of Thoracic and Abdominal Pain
por: Panday, Deepika, et al.
Publicado: (2019) -
SUN-LB026 Do CFTR Modulators Treat Cystic Fibrosis-Related Diabetes?
por: Mehfooz, Ayesha, et al.
Publicado: (2019)